Nevolat– Liraglutide Injection for Weight Management
Nevolat provides a prescription-based therapy for adults managing overweight or obesity. This peptide-based medication contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that regulates appetite and satiety. Patients experience earlier fullness during meals, reduced cravings, and controlled caloric intake, supporting gradual and sustainable weight loss.
Doctors prescribe Nevolat for adults with a body mass index (BMI) of 30 kg/m² or higher or adults with a BMI of 27 kg/m² or higher who have weight-related health conditions such as type 2 diabetes, high blood pressure, or dyslipidemia. Patients take Nevolat as part of a structured diet and exercise program. Healthcare providers monitor patient weight, blood pressure, and metabolic health to ensure safety and effectiveness.
Nevolat comes in a prefilled injection pen that allows once-daily subcutaneous administration. Patients inject into the abdomen, thigh, or upper arm. The pen provides precise dosing and supports a gradual dose escalation schedule, starting at a lower dose and increasing to the maintenance dose. This method helps patients adjust to therapy and maintain tolerability.
Using Nevolat supports appetite control, reduces energy intake, and encourages adherence to healthy lifestyle habits. Patients report decreased hunger, improved portion control, and increased confidence in weight management. Clinical studies show liraglutide therapy improves weight loss outcomes and enhances metabolic markers, including blood sugar and lipid profiles, when used under medical supervision.
Healthcare providers guide patients on dose escalation, injection technique, and ongoing monitoring. Patients achieve predictable weight loss and better long-term adherence with professional supervision. Nevolat supports behavioral changes, encourages healthier eating habits, and enhances overall lifestyle quality.
Product Specifications
| Specification | Details |
|---|---|
| Active Ingredient | Liraglutide |
| Formulation | Solution for injection in prefilled pen |
| Strength | 6 mg/mL |
| Dosage Form | Subcutaneous injection, once daily |
| Indication | Weight management in adults with BMI ≥30 or BMI ≥27 with comorbidities |
| Administration | Self-administered subcutaneous injection |
| Mechanism of Action | GLP-1 receptor agonist; regulates appetite and satiety |
| Dose Escalation | 0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg |
| Storage Conditions | Store at 2–8°C, protect from light, do not freeze |
| Common Side Effects | Nausea, vomiting, diarrhea, constipation |
| Prescription Requirement | Prescription only |
Nevolat empowers patients to actively manage weight, control appetite, and improve overall metabolic health. Its precise dosing, easy-to-use pen, and scientifically designed therapy make it a reliable choice for modern weight management.
Reviews
There are no reviews yet.